Targeted PSMA scan plus focused radiation vs radiation alone
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer with 1 to 3 symptom-free metastases (spread spots) that are small (each ≤5 cm or the total volume <250 cm³).
- Your PSMA-PET/CT scan is positive, and the spots on that scan match what was seen on your baseline CT/MRI scan.
- You must have already had treatment to the main prostate tumor (surgery and/or radiation), and prior “salvage” radiation to the prostate area or pelvis is allowed.
- Your PSMA-PET/CT scan is strong enough (SUV max at least 3) and it was done within the last 3 months.
- Your PSA and testosterone are in allowed ranges, and PSA is rising fast enough (PSA doubling time under 15 months).
- You must be 18+ and well enough to participate (low limits on blood counts and liver/kidney tests, and overall health status ≤2), with at least 6 months of expected survival.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
This trial tests a radioactive drug (PSMA-RLT) given before surgery for prostate cancer that has spread to a few spots. It aims to see if this treatment can stop the cancer from growing further.
This trial tests a personalized form of radiation therapy that targets a protein called PSMA found on some cancer cells. It may help people whose cancer has spread or cannot be removed with surgery, and has not responded to other treatments.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.